International Journal of Clinical Oncology

, Volume 11, Issue 2, pp 82–89

Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma

Authors

    • Department of Hepato-Biliary-Pancreatic SurgeryTokyo Medical and Dental University, Graduate School of Medicine
  • Shigeki Arii
    • Department of Hepato-Biliary-Pancreatic SurgeryTokyo Medical and Dental University, Graduate School of Medicine
REVIEW ARTICLE

DOI: 10.1007/s10147-006-0566-5

Cite this article as:
Tanaka, S. & Arii, S. Int J Clin Oncol (2006) 11: 82. doi:10.1007/s10147-006-0566-5

Abstract

Hepatocellular carcinoma (HCC) is well known as a typical angiogenic tumor, especially in the moderately to poorly differentiated type. Such clinicopathological characteristics are not only useful for imaging diagnosis but are also applicable to the treatment of HCC. In addition, recent molecular studies have revealed that angiogenesis is closely related to hepatocarcinogenesis. In this review, the molecular mechanism of HCC angiogenesis and the antiangiogenic prevention of HCC are reviewed to introduce the latest trends in antiangiogenic treatment of cancers, including HCC.

Key words

Hepatocellular carcinomaAngiogenesisAngiogenic switchVEGFAngiopoietinMolecularly targeted antiangiogenic therapy
Download to read the full article text

Copyright information

© The Japan Society of Clinical Oncology 2006